Primary Immune Deficiency Treatment Consortium (PIDTC) update
نویسندگان
چکیده
منابع مشابه
Primary Immune Deficiency Treatment Consortium (PIDTC) update.
The Primary Immune Deficiency Treatment Consortium (PIDTC) is a collaboration of 41 North American centers studying therapy for rare primary immune deficiency diseases (PIDs), including severe combined immune deficiency (SCID), Wiskott-Aldrich syndrome (WAS), and chronic granulomatous disease (CGD). An additional 3 European centers have partnered with the PIDTC to study CGD. Natural history pro...
متن کاملRecognizing primary immune deficiency in clinical practice.
Primary immunodeficiency results in recurrent infections, organ dysfunction, and autoimmunity. We studied 237 patients referred for suspicion of immunodeficiency, using a scoring system based on clinical information. The 113 patients with immunodeficiency had higher scores and more episodes of chronic illnesses and were more likely to have neutropenia, lymphopenia, or splenomegaly.
متن کاملUpdate on acquired immune deficiency syndrome (AIDS)--United States.
The Centers for Disease Control (CDC) received reports of 593 cases of acquired immunodeficiency syndrome (AIDS) in the US between June 1, 1981, and September 15, 1982. Death occurred in 243 (41%) of these cases. The incidence of AIDS by date of diagnosis has roughly doubled every 6 months since late-1979, and an average of 1-2 cases are now diagnosed per day. The mortality rate for cases di...
متن کاملInternational Stroke Genetics Consortium Update.
Created in April 2007, the International Stroke Genetics Consortium (ISGC) has grown into scientific community’s global organizing force for stroke genetics, open to all who can contribute to its mission. Stroke is a leading cause of death worldwide, with 15 million people suffering a stroke per year. Intracerebral hemorrhage, which makes up 15% of all stroke in the United States, results in a ...
متن کاملUpdate on the treatment of primary immunodeficiencies.
A general review of advances in the treatment of Primary Immunodeficiencies (PID) has been performed. Treatment with immunoglobulins is indicated in cases of humoral immunodeficiencies and in selected cases of combined immunodeficiencies. The use of intramuscular immunoglobulins in the treatment of PID was abandoned after obtaining the intravenous immunoglobulins, since these are much more effe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Allergy and Clinical Immunology
سال: 2016
ISSN: 0091-6749
DOI: 10.1016/j.jaci.2016.01.051